Skip to main content

Table 1 Central composite design and experimental results

From: Multivariate optimization of liquid chromatographic conditions for determination of dapagliflozin and saxagliptin, application to an in vitro dissolution and stability studies

Run

Type

X1

X2

X3

Y1

Y2

Y3

Org. phase (%)

pH

Flow rate (mL/min)

Rs

K1

K2

1

Factor

35

6

1

1.8

1.57

2.36

2

Center

30

5

0.8

3.64

5.11

6.3

3

Factor

25

6

1

10.5

1.59

3.07

4

Factor

25

4

1

8.6

7.8

8.2

5

Factor

35

6

0.6

6.2

4.53

4.9

6

Center

30

5

0.8

3.61

5.12

6.35

7

Center

30

5

0.8

3.54

5.18

6.31

8

Axial

38.5

5

0.8

1.4

1.2

2.3

9

Factor

35

4

1

1.4

2.33

2.59

10

Center

30

5

0.8

3.57

5.06

6.21

11

Factor

25

4

0.6

11.1

10.1

11.3

12

Center

30

5

0.8

3.42

5.3

6.38

13

Factor

35

4

0.6

1.8

3.2

4.6

14

Axial

30

3.31

0.8

6.4

6.6

9.3

15

Center

30

5

0.8

3.57

5

6.29

16

Axial

30

5

1.14

1.8

2.74

3.17

17

Axial

30

6.68

0.8

8.7

3.2

5

18

Axial

30

5

0.46

10.8

7.9

10.2

19

Factor

25

6

0.6

11.1

5.4

8.5

20

Axial

21.6

5

0.8

1.0

6.2

7.9

  1. X1, X2, X3 factors; Y1, Y2, Y3 responses; Rs resolution; K1 capacity factor of dapagliflozin; K2 capacity factor of saxagliptin